Taysha Gene Therapies Inc
TSHA
NASDAQ
Biotechnology
$5.95
USD
-0.04 (-0.67%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.95B
Volume 2.1M
Revenue
$5.49M
TTM
-32.3%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-149.63M
TTM
-61.4%
YoY
Operating Cash Flow
$-132.19M
TTM
-61.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 2.0 | 0.0 | 5.5 | 0.0 | 0.0 |
YoY Growth | +78.6% | -100.0% | +171.3% | -100.0% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 2.0 | 0.0 | 5.5 | 0.0 | 0.0 |
Selling, General & Administrative | 8.6 | 8.3 | 8.8 | 9.7 | 12.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | -3.4 |
Total Operating Expenses | 28.7 | 34.0 | 33.8 | 43.5 | 47.3 |
Operating Income | -26.8 | -34.0 | -28.3 | -43.5 | -47.3 |
EBITDA | -26.5 | -33.7 | -28.0 | -43.2 | -50.5 |
Other Income / Expense | -2.0 | -1.9 | -2.4 | -1.5 | -1.6 |
Total Other Income / Expense | -0.1 | 1.3 | 0.4 | 1.1 | 0.7 |
Income Before Income Taxes | -26.9 | -32.7 | -27.9 | -42.4 | -46.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -26.9 | -32.7 | -27.9 | -42.4 | -46.6 |
Consolidated Net Income / Loss | -26.9 | -32.7 | -27.9 | -42.4 | -46.6 |
Net Income Attributable to Common Shareholders | -26.9 | -32.7 | -27.9 | -42.4 | -46.6 |
Basic EPS | -$0.09 | -$0.09 | -$0.08 | -$0.12 | -$0.13 |
Diluted EPS | -$0.09 | -$0.09 | -$0.08 | -$0.12 | -$0.13 |
Basic Shares Outstanding | 298.0M | 353.3M | 358.2M | 366.6M | 369.0M |
Diluted Shares Outstanding | 298.0M | 353.3M | 358.2M | 366.6M | 369.0M |